NVS - Novartis AG

NYSE - NYSE Delayed Price. Currency in USD
75.40
-1.01 (-1.32%)
At close: 4:02PM EDT

75.40 0.00 (0.00%)
After hours: 5:35PM EDT

Stock chart is not supported by your current browser
Previous Close76.41
Open75.60
Bid75.35 x 900
Ask75.40 x 1800
Day's Range74.97 - 76.00
52 Week Range64.78 - 86.30
Volume6,892,560
Avg. Volume2,574,301
Market Cap176.431B
Beta (3Y Monthly)0.69
PE Ratio (TTM)14.01
EPS (TTM)5.38
Earnings DateN/A
Forward Dividend & Yield2.83 (2.95%)
Ex-Dividend Date2019-03-04
1y Target Est97.00
Trade prices are not sourced from all markets
  • A Second Baby Died In A Gene Therapy Study — Slugging This Biotech Stock
    Investor's Business Daily2 hours ago

    A Second Baby Died In A Gene Therapy Study — Slugging This Biotech Stock

    A second baby reportedly died in a study of Novartis' gene therapy, Zolgensma — sending shares of biotech Regenxbio into free fall Monday. Regenxbio lost nearly 8% by the closing bell.

  • Pfizer Stock Suffers From an Underappreciated Drugs Pipeline
    InvestorPlace12 hours ago

    Pfizer Stock Suffers From an Underappreciated Drugs Pipeline

    When Pfizer (NYSE:PFE) won its first approval for cancer drug Ibrance back in February 2015, as a treatment for ER+/HER2- breast cancer, investors were cautiously optimistic. PFE stock holders knew it worked well enough for a narrow subset of breast cancer patients, but expectations for the then-nascent therapy were clearly high.Source: Maciek Lulko (Modified)The drug hasn't disappointed. Since early 2015, Ibrance has been approved for three more indications, with the most recent one taking shape just this month. As it turns out, the treatment has proven effective as a therapy for some of the rare cases where men develop breast cancer.It's a testament to the drug's incredible versatility and efficacy.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAnd yet, while Ibrance is still in trials looking for even more approved uses, the company's future hardly hinges on what's quickly turning into a blockbuster drug. The market is largely overlooking much of Pfizer's pipeline. Catalysts AheadBank of America Merrill Lynch analyst Jason Gerberry made the point of making the call three weeks ago, upping the brokerage firm's price target on PFE stock from $45 to $48 on upcoming catalysts related to the development of two orphan drugs.Orphan drugs, in short, take aim at underserved areas of the pharmaceutical market. In many cases there are so few cases of a particular illness that no pharmaceutical company bothers developing an option, so when one does, the FDA facilitates an easier path to approval; something is better than nothing.One such drug in Pfizer's pipeline is Vyndaqel.It's not a new drug. In fact, it was first approved back in 2011. Its potential use as a treatment for cardiomyopathy, however, is in the works, and is expected to launch later this year to a receptive caregiver environment.All told, BofA-ML's Gerberry sees peak sales of $2 billion for Vyndaqel.Gerberry also notes that a Pfizer gene therapy candidate -- PF-06939926 for Duchenne muscular dystrophy -- is closer to the endzone than many current and would-be owners of PFE stock may realize. Though in Phase 1 testing right now, should the R&D update slated for the middle of the year go as well as expected, the drugmaker may be able to leap straight to Phase 3 trials and catch up with a similar development from DMD rival Sarepta Therapeutics (NASDAQ:SRPT). * 7 High-Risk Stocks With Big Potential Rewards Again, it's not only another catalyst that could draw a bullish crowd, but it's also a development that could put real revenue growth on the table real soon. The Duchenne muscular dystrophy market could be worth more than $4 billion by 2023.Outside of Gerberry's discussion, Pfizer's Vizimpro was approved earlier this month in Europe as a first-line treatment of locally advanced or metastatic non-small cell lung cancer.Pfizer's still got its R&D, or at least its therapy-acquiring, chops. Heavy HittersThough PF-06939926 and Vyndaqel should prove to be solid bolt-on revenue and profit centers, there's still little doubt that Ibrance will be the company's heavy hitter -- and growth driver -- for the foreseeable future.As of the company's most recent quarterly report, 12-month revenue for the wonder drug reached $4.1 billion, up 32% from the trailing-12-month figure reported a year earlier. New approvals and expanded usage for previously approved indications both helped.The drug, though, has still only scratched the surface. Some analysts are calling for peak revenue of around $8 billion before Ibrance runs out of room to grow and is crimped by rival drugs.Again, that potential is a testament to the drug's flexibility.Ibrance isn't the only heavy-hitter still in growth mode in Pfizer's lineup though. While Enbrel (sold by Pfizer in Europe), Sutent and Celebrex may all be major names with declining revenue, sales of fibromyalgia treatment Lyrica appear to have stabilized around an annual pace of $4.6 billion. Ditto for pneumococcal bacteria treatment Prevnar, which has driven more than $5 billion in sales over the course of the past four reported quarters.In the meantime, Pfizer has started to shine in an area that had quietly gnawed at PFE stock owners… biosimilars. The company has sold $642 million worth of ulcerative colitis, arthritis and plaque psoriasis drug Inflectra/Remsima over the past year, up 50% year-over-year, and suggesting it doesn't have to yield to the pharmaceutical industry's biosimilar powerhouses like Novartis (NYSE:NVS) and Amgen (NASDAQ:AMGN). * 7 Stocks to Buy for Spring Season Growth Pfizer's got five biosimilar drugs in the works, positioning it for deeper penetration of an admittedly-crowded market forecasted to be worth more than a stunning $60 billion by 2024. Bottom Line for PFE StockPFE stock is down 15% from its November peak, never really rebounding with the rest of the market beginning in January. Shares are down 10% just since early April, as the future of U.S. health care has become blurred by political rhetoric. Indeed, Pfizer stock hasn't made net progress since the middle of last year. Clearly there's something wrong with the company.Or, maybe there isn't.Though the headlines and sentiment seem dire, that pessimism is largely rooted in investors' collective view that sees a glass as half-empty rather than half-full. Pfizer's got a quietly potent pipeline, though, with a mix of already-approved and new drugs closer to wrapping up clinical trials than many investors might realize.That may not be enough to stave off headline-driven headwinds in the short run. But, there's a reason a streak of downgrades late last year has been countered this year with a couple of upgrades to an "Outperform'" rating.One of those upgrades came from Credit Suisse, with analyst Vamil Divan noting that patent woes working against aforementioned therapies like Enbrel and Celebrex are starting to abate at the same time new therapies are reaching their full stride.It's just a story not many investors are paying attention to right now.As of this writing, James Brumley did not hold a position in any of the aforementioned companies. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Dividend Stocks Perfect for Retirees * 7 Reasons the Stock Market Rally Isn't Over Yet * 10 S&P 500 Stocks to Weather the Earnings Storm Compare Brokers The post Pfizer Stock Suffers From an Underappreciated Drugs Pipeline appeared first on InvestorPlace.

  • Reuters3 days ago

    Second death in Novartis gene therapy trials under investigation

    Novartis AG, which this week announced positive interim trial results for its experimental gene therapy for spinal muscular atrophy, on Friday said investigation is underway into whether a second trial death could be related to the treatment. Novartis has filed for U.S. Food and Drug Administration approval of the gene therapy, Zolgensma, and a decision is expected within weeks. The FDA submission was based on findings from a trial of 15 babies treated with Zolgensma.

  • Top Gene-Sequencing Stocks for 2019
    Motley Fool3 days ago

    Top Gene-Sequencing Stocks for 2019

    These next-generation companies are working on game-changing ways to obtain and profit from genetic insight.

  • 3 Top Dividend Stocks to Buy Right Now
    Motley Fool3 days ago

    3 Top Dividend Stocks to Buy Right Now

    Sometimes you have to act while the iron's hot, and that's the case with these three big-name dividend payers right now.

  • The Top 10 Biotechnology Companies (JNJ, ROG.VX)
    Investopedia4 days ago

    The Top 10 Biotechnology Companies (JNJ, ROG.VX)

    Learn how the marriage of science and technology is changing the world of medicine and creating some of the largest multinational biotechnology corporations.

  • Roche's (RHHBY) Q1 Sales Strong on Solid Demand for New Drugs
    Zacks4 days ago

    Roche's (RHHBY) Q1 Sales Strong on Solid Demand for New Drugs

    Roche's (RHHBY) performance in the first quarter of 2019 is driven by solid strength of new drugs, which more than offset competition from biosimilars.

  • Why A Highly Rated Biotech With A 54% Gain This Year Is Being Gutted
    Investor's Business Daily5 days ago

    Why A Highly Rated Biotech With A 54% Gain This Year Is Being Gutted

    Ionis Pharmaceuticals was slammed Wednesday on competitive gene-therapy data from Novartis' AveXis unit and amid apparently disappointing comments from Roche in Huntington's disease.

  • Here's Why Ionis Pharmaceuticals Slumped Today
    Motley Fool5 days ago

    Here's Why Ionis Pharmaceuticals Slumped Today

    Information from competitors and a collaborator sent the high-flying biotech lower.

  • Benzinga5 days ago

    The Daily Biotech Pulse: Zolgensma Data, Roche Q1 Results, Brainsway IPO

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 16) Eidos Therapeutics Inc (NASDAQ: EIDX )(reported fourth ...

  • Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran
    Zacks6 days ago

    Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran

    Alnylam (ALNY) initiates phase III study on lumasiran and also reports new positive efficacy results from the ongoing phase II open-label extension (OLE) study on the same.

  • Radius Health (RDUS) Rallies 33.4% YTD on Robust Tymlos Sales
    Zacks6 days ago

    Radius Health (RDUS) Rallies 33.4% YTD on Robust Tymlos Sales

    Radius Health's (RDUS) lead drug, Tymlos, gains traction in 2018. Let us see how the drug will fare in 2019 amid increasing competition.

  • Marijuana ETF Down 9% in Past Month: Time to Enter the Space?
    Zacks6 days ago

    Marijuana ETF Down 9% in Past Month: Time to Enter the Space?

    Growing global acceptance, increasing legalization and beaten-down prices open up room for marijuana ETF investing.

  • Allergan Falls as Supreme Court Dismisses Restasis Litigation
    Zacks6 days ago

    Allergan Falls as Supreme Court Dismisses Restasis Litigation

    Allergan's (AGN) key drug, Restasis' prospects hurt as the U.S. Supreme Court upholds the ruling of a lower court, which invalidated certain patents protecting the drug.

  • Novartis' (NVS) BLA for Ophthalmology Drug Accepted by FDA
    Zacks6 days ago

    Novartis' (NVS) BLA for Ophthalmology Drug Accepted by FDA

    The FDA accepts Novartis' (NVS) BLA seeking approval for brolucizumab for the treatment of wet AMD.

  • Benzinga6 days ago

    The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 15) Amneal Pharmaceuticals Inc (NYSE: AMRX ) Biohaven ...

  • Alnylam (ALNY) Reports Phase III ENVISION Data on Givosiran
    Zacks7 days ago

    Alnylam (ALNY) Reports Phase III ENVISION Data on Givosiran

    Alnylam (ALNY) reports complete positive results from the phase III ENVISION study of givosiran for the treatment of acute hepatic porphyria.

  • Barrons.com7 days ago

    Alcon Stock Is Back. The Eye-care Company Deserves a Long, Hard Look.

    Newly spun off from Novartis, the eye-care giant has strong growth potential and is better off as an independent company.

  • Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal
    Zacks10 days ago

    Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal

    Glaxo (GSK) gets FDA approval for a new HIV medicine, Dovato. AstraZeneca (AZN)/Merck's (MRK) Lynparza gets approval in EU for metastatic breast cancer.

  • Ophthotech Gets Rights to Gene Therapy for BEST Disease
    Zacks10 days ago

    Ophthotech Gets Rights to Gene Therapy for BEST Disease

    Ophthotech (OPHT) obtains development/commercialization rights to AAV gene-therapy program for BEST1-related retinal diseases from Penn and UFRF.

  • Novartis to Market Rizmoic Through Sandoz, Spins Off Alcon
    Zacks11 days ago

    Novartis to Market Rizmoic Through Sandoz, Spins Off Alcon

    Novartis' (NVS) Sandoz signs an agreement with Japanese company, Shionogi, to commercialize constipation drug in key European markets.

  • Biotechnology Market on a Tear: 5 ETFs in Spotlight
    Zacks11 days ago

    Biotechnology Market on a Tear: 5 ETFs in Spotlight

    Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.

  • Top Research Reports for McDonald's, Enterprise Products & Charles Schwab
    Zacks11 days ago

    Top Research Reports for McDonald's, Enterprise Products & Charles Schwab

    Top Research Reports for McDonald's, Enterprise Products & Charles Schwab

  • Intercept Reports Additional Positive Data From NASH Study
    Zacks11 days ago

    Intercept Reports Additional Positive Data From NASH Study

    Intercept Pharmaceuticals (ICPT) reports positive additional supportive data from its phase III REGENERATE study of obeticholic acid in patients with liver fibrosis due to NASH.

  • Here’s the Real Problem with Altria Overpaying for CRON Stock
    InvestorPlace11 days ago

    Here’s the Real Problem with Altria Overpaying for CRON Stock

    Canadian-based marijuana company Cronos (NASDAQ:CRON) soared earlier this year, but Cronos stock is falling back to earth as the frenzy dies down.Source: Shutterstock The rise in CRON stock mostly is attributable to interest from Altria (NYSE:MO). The owner of veteran cigarette brands Marlboro, Parliament, and Virginia Slims got into the game with a $1.8 billion investment in Cronos.At the time of transaction, Altria's $1.8 billion investment translated roughly to a 45% ownership of Cronos with warrants to own up to 55% of the company, which Altria has the option to exercise anytime in the next four years.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 8 Risky Stocks to Watch as Earnings Season Kicks Off Altria's controlling interest in Cronos takes place on the heels of two high-profile investments in marijuana stocks in 2018. Constellation Brands (NYSE:STZ), the maker of Corona and Modelo beer, was arguably the first-mover in sealing a deal for a 38% stake in Canopy Growth (NYSE:CGC).Late in the year, it was Switzerland-based Big Pharma company, Novartis (NYSE:NVS) that threw its hat in the cannabis ring, announcing a partnership with Tilray (NASDAQ:TLRY).As the above transactions show, suitors interested in investing in the cannabis sector run the gamut. From alcoholic beverage companies to large pharmaceutical companies and now to Big Tobacco. Many industries are already feeling the initial wave of marijuana legalization across certain states within the U.S. impact sales.Amidst declining sales, Altria was left then, with no choice but to get on the bandwagon. CRON Stock Hits the Big TimeLooking closer at the data though, in Altria's case there seems to have been a case of FOMO (fear of missing out). To begin with, publicly-traded cannabis companies on major U.S. are a recent novelty. Before, Canadian-listed marijuana stocks that wanted to appeal to the broader U.S. investor base were relegated to over-the-counter exchanges. This change has made these cannabis investments more palatable for shareholders.Because U.S. exchanges like the New York Stock Exchange and tech-focused NASDAQ will not list companies that break U.S. federal law, U.S.-based cannabis companies find themselves at a disadvantage in raising capital compared to their northern counterparts. Marijuana is legal in Canada, so as long as these Canadian-based marijuana companies stick to operating there, they aren't violating any laws in the jurisdictions they operate in. While U.S. companies salivate over the kinds of money and high valuations that Canadian companies have gotten, the fact is that I can see a future in which U.S. competitors in the space no longer have to go to the Canadian TSX to raise money. Once they are able to list on U.S. Exchanges, companies interested in the cannabis space will have a larger pool of partners to choose from.Potentially, these partners will generate more synergies as well given their knowledge and scale within the domestic market.Before that future comes to pass, however, Altria may have felt that it was a do or die situation. MO seemed like to would be willing to pay any amount to get a toehold in the rapidly-growing cannabis sector. Altria Overpays for CRON StockWith CGC and TLRY already off the market, Altria jumped for CRON.There are certainly synergies across Altria's core business with cannabis than with beer. Still it is hard to justify paying a price to sales multiple of 267x (compare that to CGC's 86x).If we look at a less conventional metric: market capitalization to kilograms of cannabis sold, it gives an idea of the comparatively stratospheric valuation that Altria paid.Last fiscal year, CRON sold 2,737 kilograms of dry cannabis. Using an estimated price of $15 per share from when Altria announced the deal late last year and March of this year when they closed the deal and outstanding shares of 333 million, a market cap figure emerges of $5 billion. Do the division and Altria paid an estimated $1.8 million per kilogram of cannabis sold. Sound high?Doing the same exercise with CGC while adjusting for an earlier timeframe since the acquisition closed last year, I use trailing twelve months kilograms sold of 9,750 and 177 million outstanding shares. The result is $545,000 market capitalization/kilogram, less than a third of what Altria paid for CRON. The Final Word on CRON StockRight now, there are a lot of projects underway that will decide if the CRON investment is ultimately accretive. There is the much-touted supply agreement with Cura Cannabis Solutions, for example.Remember though, this five year take-or-pay supply agreement to purchase a minimum of 20,000 kilograms of cannabis per annum from Cronos can only take place after Cura receives all necessary licenses from Health Canada.There's also the potential 120-acre facility in Australia that is under review. If completed, the expected annual production capacity is 2,000 kilograms. And let's not forget the 850,000 sq. ft. Ontario-based greenhouse that is expected to have a 70,000 kilograms capacity.Overall, this is probably still a net positive for Altria shareholders as they'll benefit from the growth profile and exposure to cannabis. The price tag, however, will be hard to justify if CRON stock doesn't deliver on its growth projections.As of this writing, Luce Emerson did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Medical Marijuana Stocks to Cure Your Portfolio * 8 Best Stocks to Buy for an April Rally * Top 20 Stocks to Buy for 20-Somethings! Compare Brokers The post Here's the Real Problem with Altria Overpaying for CRON Stock appeared first on InvestorPlace.